little is known about anorectal function and quality of life after chemoradiation followed by local excision, which is an alternative to total mesorectal excision for selected patients with early rectal cancer.
R adical surgery with total mesorectal excision (tme), the standard of care for patients with early rectal cancer, 1 is associated with significant mor-bidity and anorectal functional impairment that may significantly reduce health-related quality of life (hRQol). [2] [3] [4] functional impairment is especially common among patients with distal rectal tumors who undergo either an abdominoperineal resection with a permanent colostomy or a low colorectal or coloanal anastomosis. such low anastomoses are often associated with particularly distressing symptoms, including defecatory urgency, clustering of bowel movements, stool fragmentation, and fecal incontinence. 5 in patients with early stage rectal cancers limited to the bowel wall, organ-preserving management approaches, such as chemoradiation (CRt) and local excision (le) are potentially both curative and effective in avoiding the sequelas and morbidity of tme. 6, 7 le has a limited impact on anorectal function (af), 8 but CRt administered after tme has been shown to impair af compared with tme alone. 9 By extrapolation, there is a possibility that CRt may also affect af in patients who undergo le. Currently, prospective high-quality data on af and hRQol in patients treated with preoperative CRt followed by le are lacking.
the american College of surgeons oncology Group (aCosoG) Z6041 phase ii trial investigated the outcomes of neoadjuvant CRt with a capecitabine/oxaliplatin regimen followed by le in patients with stage ct2n0 rectal cancer. the results of the study's primary end point of 3-year disease-free survival have been published recently. oncologic outcomes were comparable with those of patients in a previously published series who had tumors of a similar stage that were treated with tme. 10 although our previous report included only a summary of hRQol and af results, here we report the full hRQol and af data from patients included in this trial, with comparison of results at baseline to the data obtained from postoperative assessment at 1 year. 10 
PATIENTS AND METHODS
the study design, inclusion criteria, and treatment interventions, as well as pathological, surgical, and oncological outcomes of the Z6041 trial, have been reported previously. 10, 11 in summary, the study enrolled patients with rectal adenocarcinoma, staged as ct2n0 via endorectal ultrasound or endorectal-coil mRi, and with tumors that were located within 8 cm of the anal verge, were <4 cm in maximal diameter, and occupied <40% of the rectal circumference. initially, eligible patients underwent neoadjuvant CRt with a total radiation dose of 50.4 or 54.0 Gy and chemotherapy consisting of capecitabine and oxaliplatin (original-dose group). Because of an unfavorable toxicity profile, neoadjuvant treatment was adjusted during the study; the revised-dose group received a reduced dose of external beam radiotherapy (from 54.0 Gy to 50.4 Gy) and capecitabine (from 825 mg/m  2 on days 1-14 and 22-35 to  725 mg/m 2 twice a day, 5 days per week, for 5 weeks). Patients were scheduled to undergo either conventional transanal excision or transanal endoscopic microsurgery, at the discretion of the surgeon, within 4 to 8 weeks after CRt completion. adverse events (aes) related to CRt or surgery were recorded and reported according to the national Cancer institute Common terminology Criteria for adverse events, version 3.0.
12 after surgery, tumors were staged according to american Joint Committee on Cancer criteria. 13 Patients with ypt0 to t2 n0 tumors and negative margins were followed. Patients with ypt3 tumors, positive nodes, or positive margins were treated at the discretion of the supervising physician, and alternative surgical options, including tme, were considered. Patients were clinically evaluated every 4 months for 3 years and subsequently every 6 months for the following 2 years. Proctoscopy and endorectal ultrasound were performed at the physician's discretion. Colonoscopy was performed 3 years after initial surgery.
af and hRQol were evaluated before treatment at the time of enrollment (baseline) and at 12 months after surgery. af was assessed using the fecal incontinence severity index (fisi), a validated instrument that addresses the frequency of leakage of gas, mucus, liquid, or solid stool, with higher scores indicating worse af.
14 hRQol was evaluated using 2 instruments. the first was the functional assessment of Cancer therapy-Colorectal (faCt-C), a validated questionnaire that contains 34 items related to 5 subscales, including physical well-being (7 items), social/family wellbeing (7 items), emotional well-being (6 items), functional well-being (7 items), and the colorectal cancer subscale (CCs; 7 items). a higher score reflects better hRQol and overall function. Physical well-being, social/family wellbeing, and CCs were used to calculate the trial outcome index (toi), which better reflects the true impact of the treatment intervention. 15 the second hRQol-validated instrument was the fecal incontinence Quality-of-life scale (fiQl), which is composed of 29 items evaluating 4 subscales, including lifestyle (10 items), coping/behavior (9 items), depression/self-perception (7 items), and embarrassment (3 items). scores for each item range from 0 (worst) to 4 (optimal). scores are calculated as the mean numeric response to all of the items within each scale, with a maximum possible overall score of 4. 16 Descriptive summary statistics of hRQol and af at baseline and at 12 months after surgery were compared using Wilcoxon signed-rank tests. Minimally important differences in faCt-C scores were calculated according to previously reported methods. Differences of 2 to 3 points in the CCs, 4 to 6 in toi, and 5 to 8 in the overall faCt-C score were considered clinically relevant. 17 multivariate logistic regression analyses were performed using variables considered relevant to outcome, adjusting for baseline scores. the variables considered were age, sex, pathologic complete response status (ypt0), treatment dose (original vs revised), surgical approach (transanal excision vs transanal endoscopic microsurgery), tumor distance from the anal verge, and aes during CRt or postoperatively. all of the statistical analyses were performed with sas software (version 9.2; sas institute inc, Cary, nC); p values <0.05 were considered statistically significant.
RESULTS
seventy-nine eligible patients were accrued for the trial and started treatment. the patient disposition and trial profile have already been published. 10 seven of 79 patients did not have le (n = 2) or ultimately underwent tme for high-risk pathologic findings (n = 5). the remaining 72 patients were treated with CRt and le and compose the eligible study cohort.
of the 72 eligible patients, 71 completed a baseline evaluation of af and hRQol, and 66 (92%) completed evaluations at 12 months after surgery. of the 6 patients who did not complete the 12-month postoperative evaluation of af and hRQol, 1 patient died (8 months after surgery), 1 refused to complete the evaluation forms, and 4 missed the follow-up appointment and did not reschedule. the median age of those who completed both baseline and 12-month postoperative assessments was 63 years (range, 30-83 years); 47 patients (66%) were men. forty-nine patients (69%) were treated with the original treatment dose, and 22 (31%) received the revised dose.
thirty-four patients (47%) were found to have no residual tumor cells on pathological examination (ypt0). fortysix patients (65%) underwent conventional transanal excision, and 25 (35%) underwent transanal endoscopic microsurgery. overall, 38 patients had at least 1 grade 3 or higher ae; 34 patients (48%) had at least 1 grade 3 or higher ae during CRt, and 9 patients (13%) had at least 1 grade 3 or higher ae in the perioperative period (table 1) . aes have been described in detail previously. 11 at the 12-month postoperative evaluation, no significant change was observed in the overall fisi score and its subdomains compared with baseline scores (table 2) . a waterfall plot analysis shows that the proportion of patients who experienced a deterioration in af and the proportion of patients who experienced an improvement were similar ( fig. 1) .
the fiQl showed significantly worse outcomes in the lifestyle, coping/behavior, and embarrassment scales. of note, the depression scale values did not change significantly. a waterfall plot analysis for the 4 categories of the fiQl questionnaire is shown in figure 2 .
finally, overall faCt-C scores 1 year after surgery were not significantly different from baseline (p = 0.75). although the overall score did not change for the entire group, waterfall plot analyses indicate that half of the patients experienced an improvement and the other half a deterioration ( fig. 3 ). the social/family well-being, functional well-being, and CCs sub- domains also showed no significant differences. there was a statistically significant deterioration in the physical well-being subdomain (25.2 vs 23.8; p = 0.03), whereas there was a significant improvement in the emotional well-being subdomain (18.6 vs 20.1; p = 0.02). according to previously established minimally important differences, 19 patients (32%) presented a clinically significant decrease in the overall faCt-C score, 23 (38%) in the CCs score of the same questionnaire, and 22 (37%) in the toi. on the other hand, 20 (33%) had clinically significant improvement in the overall faCt-C score, 17 (28%) in the toi score, and 17 (28%) in the CCs score. none of the variables analyzed were predictors of a deterioration of the overall fisi score. in both univariate and multivariate analyses, treatment with the original CRt regimen was associated with worse outcomes in the depression/self-perception and embarrassment domains of the fiQl questionnaire. male sex was the only variable associated with worse overall faCt-C score in the univariate and multivariate analyses (table 3) .
DISCUSSION
this study shows that the whole cohort of patients with ct2n0 rectal cancer treated with CRt and le did not experience a significant deterioration in af as assessed by the fisi score 1 year after surgery compared with baseline. this is explained by the fact that the proportion of patients who experienced a deterioration on this score was similar to the proportion of patients who had better results. in contrast, patients reported deterioration in all domains of the fiQl questionnaire, except for the depression/self-perception domain. finally, the whole cohort did not report a deterioration in hRQol measured with the overall faCt-C score; on the basis of this score, the numbers of patients improving and deteriorating were similar. although patients reported deterioration in the physical well-being subdomain of the faCt-C questionnaire, they also had better scores in the emotional well-being subdomain.
our findings also indicate that hRQol may be affected more by the neoadjuvant regimen than by the le method. a surprising finding of this study was the lack of correlation between the deterioration in the fiQl scores 1 year after CRt and le without a significant change in the fisi score. this discrepancy may be attributable to differences in the sensitivity of the tools used to assess fecal incontinence.
af and hRQol are important outcomes in all patients treated for rectal cancer. these outcomes are particularly important in patients with early stage tumors who are willing to trade the high cure rates associated with a tme for the better af and hRQol that one would expect with organ-preservation approaches. although many studies have reported on af and hRQol in patients treated with le alone, the number of studies investigating these outcomes after CRt and le is limited. in our study, mean scores for all domains of the fiQl questionnaire were worse than those reported for patients with early rectal cancers or with benign conditions treated with transanal endoscopic microsurgery alone. 18 these differences are to some degree expected, because the combination of radiation and surgery is associated with greater complete response. the investigators reported excellent results, with near-optimal continence and evacuative scores. however, baseline af was not collected, and the instruments used had not been validated previously. 20 in contrast, a more recent study from Poland reported significantly worse af among 44 patients who underwent preoperative radiation and le. in that study, anorectal dysfunction symptoms experienced by patients included incontinence to flatus (51%), clustering of bowel movements (49%), incontinence to loose stools (46%), and urgency (49%). in all, 21% of patients experienced anorectal dysfunction classified as severe. as in the italian study, af was assessed using a nonvalidated questionnaire, and, therefore, the results could not be compared with other series. of note, patients in the Polish study were treated with short-course radiation (25 Gy in 5 fractions over 1 week, followed by a 4-Gy boost in a single fraction). it is possible that the differences in the radiation protocol may explain the differences in outcomes between studies. 21 a recent phase 1b-ii trial investigating the efficacy of short-course radiation and le for patients with stage i rectal cancer was closed before completing accrual because of unexpected high-grade shortterm toxicity. 22 it is possible that the higher-grade short-term toxicity associated with short-course radiation may result in higher rates of long-term anorectal dysfunction.
a number of studies have investigated af and hRQol in patients with rectal cancer treated with neoadjuvant therapy and tme, but only a few have used the same validated instruments as those used in the Z6041 study protocol, limiting possibilities for comparisons between studies. in a multinational, prospective study, fazio et al 23 assessed bowel function using the fisi questionnaire in patients with low rectal cancer who had a coloanal anastomosis with or without colonic reservoir. fisi scores at 12 months in all of the arms of the trial by fazio et al 23 ranged from 35 to 50 and were significantly higher than the score reported by our patients (average of 28). these data suggest that the impact of CRt and le in fecal continence is less than that of sphincter-saving tme independent of the type of colorectal anastomosis. the fiQl results observed among our patients compare favorably with those of patients with rectal cancer treated with CRt and tme, regardless of whether they experienced surgical complications. 24 these findings suggest that patients with rectal cancer treated with CRt and le experience a lesser deterioration in af and hRQol, as assessed by the fisi and the fiQl scores, than patients treated with tme. a recently published report of patient-reported outcomes from the national surgical adjuvant Breast and Bowel Project (nsaBP) R04 trial showed no significant differences in faCt-C at 1 year compared with baseline after neoadjuvant CRt and tme. 25 surprisingly, mean scores in the enrolled patient population did not change significantly from baseline to 1 year after surgery, regardless of whether an abdominoperineal resection or a sphincter- saving surgery had been performed. nsaBP R04 patient scores were also similar to those of the Z6041 patients who were treated with an organ-sparing procedure. this similarity in baseline and 1-year posttreatment scores in both the nsaBP and aCosoG studies suggests that the faCt-C score may lack the sensitivity required to detect differences in patients with rectal cancer who are treated with different procedures.
our study also revealed that the more toxic original neoadjuvant treatment regimen was independently associated with a worse score in the embarrassment domain in the fiQl. Because the dose of oxaliplatin was equivalent in the 2 regimens, this observation suggests that the intensity of the neoadjuvant therapy independent of the dose of oxaliplatin may impact Qol both permanently and independently. on the other hand, we can only speculate about the cause of sex differences in the overall score and the toi of the faCt-C questionnaire. Because of associated toxicities without a significant survival benefit, subsequent trials have abandoned the use of oxaliplatin in the neoadjuvant setting.
the strengths of our study are the prospective data collection before and after treatment, the use of validated questionnaires, and the high rate of questionnaire completion by the patients. however, there are also limitations. first, the number of patients is relatively small. second, our 1-year follow-up period is relatively short. however, other studies have shown that af and hRQol seem to stabilize 1 to 2 years after treatment and deteriorate slowly thereafter. 26 third, baseline scores were obtained when the patients already had a tumor in the rectum. the impact of the tumor on af and some domains of hRQol is unknown. this might explain why some patients got better functional and hRQol outcomes after treatment. fourth, no objective measurement of bowel function, such as anorectal manometry, was performed. although manometric findings often do not correlate with clinical outcomes, such an evaluation may have provided a more accurate assessment of the impact of this treatment modality in anal sphincter function. finally, af and hRQl were secondary outcomes of the aCosoG Z6041 trial. Because the information available about aRf and hRQol for patients with early stage rectal cancer treated with CRt and le at the time of the study design was limited, no power calculation was performed for these outcomes.
Despite these limitations, the results of this trial should be used to inform presurgical patient discussions regarding expected af and hRQol outcomes of this treatment strategy. these findings may also be applied to future trial design for studies comparing outcomes of neoadjuvant CRt and le with other treatment modalities.
CONCLUSION
in our cohort of patients with ct2n0 low rectal cancer treated with le after CRt, the proportion of patients with worse af according to the fisi score 1 year after surgery was similar to the proportion of patients with better results. however, during the same postoperative period, patients reported a slight decrease in hRQol in some domains of the fiQl and faCt-C scoring systems. on the faCt-C questionnaire, two thirds of the patients undergoing CRt and le reported the same or better hRQol 1 year after surgery. male sex and more aggressive neoadjuvant therapy may have an impact on final hRQol outcome. 
